BioSpace News Archive

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced first quarter 2022 results and provided a business update.

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. (“Atrin”) and reported financial results for the three months ended March 31, 2022.

In preclinical animal studies, NVG-291 has demonstrated the potential to promote repair mechanisms in the nervous system, including plasticity, axonal regeneration, and remyelination.

Revolo Biotherapeutics announced that the Company will be delivering presentations at two upcoming medical meetings: the American Thoracic Society International Conference and the Treg Summit.

Focused Ultrasound, an innovative, new procedure being used by USF Health Morsani College of Medicine neurosurgeons at Tampa General Hospital for the first time in the region offers promising treatment for people suffering from essential tremor, Parkinson’s disease, and other debilitating neurological disorders.

CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy (DMD), today released a webinar on the upcoming opening of U.S. trial sites for Pfizer’s CIFFREO trial, a phase 3 study in ambulatory boys with DMD to assess the safety and efficacy of an investigational mini-dystrophin gene therapy.

The U.S. Food and Drug Administration authorized the Labcorp Seasonal Respiratory Virus RT-PCR DTC Test for use without a prescription by individuals with symptoms of respiratory viral infection consistent with COVID-19.

WallachBeth Capital LLC announced the completion of the purchase and sale of 2,000,000 shares of common stock of ABVC BioPharma, Inc., and warrants to purchase up to 2,000,000 shares of common stock, at a purchase price of $2.11 per share in a registered direct offering for total gross proceeds of $4.22 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

GBS Inc. announced that Dr. Steven Boyages, GBS’ interim CEO and Chairman of the Board, along with other management team members will participate at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022 and invites investors to participate via virtual one-on-one meetings.

Acer Therapeutics Inc. reported financial results for the first quarter ended March 31, 2022 and provided an update on the Company’s recent corporate developments.